Haleon (LON:HLN) Price Target Lowered to GBX 315 at JPMorgan Chase & Co.

Haleon (LON:HLN) had its price target dropped by research analysts at JPMorgan Chase & Co. from GBX 335 to GBX 315 in a report released on Thursday,London Stock Exchange reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential downside of 9.59% from the company’s previous close.

Several other equities research analysts have also issued reports on HLN. Berenberg Bank reissued a “buy” rating and issued a GBX 512 price target on shares of Haleon in a report on Thursday, April 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a report on Thursday, April 30th. Finally, Jefferies Financial Group decreased their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Haleon currently has an average rating of “Moderate Buy” and an average price target of GBX 395.33.

Haleon Stock Up 0.1%

Shares of HLN stock opened at GBX 348.40 on Thursday. The stock has a market cap of £30.82 billion, a P/E ratio of 18.83, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. Haleon has a one year low of GBX 317.80 and a one year high of GBX 416.10. The stock has a fifty day moving average price of GBX 338.82 and a 200 day moving average price of GBX 364.11. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.